The estimated Net Worth of Michael A Henos is at least $317 mil dollars as of 19 December 2014. Michael Henos owns over 21,257 units of GlycoMimetics Inc stock worth over $75,113 and over the last 11 years Michael sold GLYC stock worth over $241,433.
Michael has made over 4 trades of the GlycoMimetics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael sold 21,257 units of GLYC stock worth $181,110 on 19 December 2014.
The largest trade Michael's ever made was selling 21,257 units of GlycoMimetics Inc stock on 19 December 2014 worth over $181,110. On average, Michael trades about 5,068 units every 33 days since 2014. As of 19 December 2014 Michael still owns at least 469,454 units of GlycoMimetics Inc stock.
You can see the complete history of Michael Henos stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG, MD, 20879.
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris y M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
GlycoMimetics Inc executives and other stock owners filed with the SEC include: